Cargando…

Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity

Growing evidence suggests water-soluble, non-fibrillar forms of amyloid-β protein (Aβ) have important roles in Alzheimer’s disease with toxicities mimicked by synthetic Aβ(1–42). However, no defined toxic structures acting via specific receptors have been identified and roles of proposed receptors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicoll, Andrew J., Panico, Silvia, Freir, Darragh B., Wright, Daniel, Terry, Cassandra, Risse, Emmanuel, Herron, Caroline E., O’Malley, Tiernan, Wadsworth, Jonathan D. F., Farrow, Mark A., Walsh, Dominic M., Saibil, Helen R., Collinge, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908552/
https://www.ncbi.nlm.nih.gov/pubmed/24022506
http://dx.doi.org/10.1038/ncomms3416
Descripción
Sumario:Growing evidence suggests water-soluble, non-fibrillar forms of amyloid-β protein (Aβ) have important roles in Alzheimer’s disease with toxicities mimicked by synthetic Aβ(1–42). However, no defined toxic structures acting via specific receptors have been identified and roles of proposed receptors, such as prion protein (PrP), remain controversial. Here we quantify binding to PrP of Aβ(1–42) after different durations of aggregation. We show PrP-binding and PrP-dependent inhibition of long-term potentiation (LTP) correlate with the presence of protofibrils. Globular oligomers bind less avidly to PrP and do not inhibit LTP, whereas fibrils inhibit LTP in a PrP-independent manner. That only certain transient Aβ assemblies cause PrP-dependent toxicity explains conflicting reports regarding the involvement of PrP in Aβ-induced impairments. We show that these protofibrils contain a defined nanotubular structure with a previously unidentified triple helical conformation. Blocking the formation of Aβ nanotubes or their interaction with PrP might have a role in treatment of Alzheimer’s disease.